Expression Changes of CX3CL1 and Interleukin-6 Genes During Remission Induction Therapy in Patients with Acute Myeloid Leukemia

• Published in: Galen 2021-12, Vol.10
• Main Authors: Vakil, Mohammad Kazem, Iravani Saadi, Mahdiyar, Ramzi, Mani, Karimi, Aliasghar, Owjfard, Maryam, Torkamani, Mahmoud, Kheradmand, Nadiya, Niknam, Ahmad, Karimi, Zahed, Yazdanpanah, Mohammad Hosein
• Format: Article
• Language: English
• ISSN: 2588-2767; 2322-2379
• DOI: 10.31661/gmj.v10i.2288

Background: Acute myeloid leukemia (AML) syndrome is a hematologic malignancy due to the extensive clonal proliferation of leukemic precursor cells and is rapidly fatal unless treated or in response to chemotherapy. Cytogenetic findings have an important role in the prognosis and categorization of AML. This study aimed to investigate the expression changes in CX3CL1 and Interleukin-6 (IL-6) genes before and after chemotherapy as remission induction therapy in AML patients. Materials and Methods: In this study, 69 patients (36 males, 33 female) with AML were selected from tertiary medical health centers. A quantitative polymerase chain reaction was performed for mRNA expression of CX3CL1 and IL-6 genes before and after induction chemotherapy using the 2-ΔΔCT method. Results: The expression of CX3CL1 and IL-6 were significantly increased after induction chemotherapy. Also, the ΔCt mean of CX3CL1 and IL-6 mRNA was not significant between AML subtype groups. Conclusion: We showed that chemotherapy significantly increases the expression of CX3CL1 and IL-6, which can be used as a prognostic factor of AML. [GMJ.2021;10:e2288]